April 2024

Improving Vision in Congenital Nystagmus – Pivotal RCT Results – AAPOS 2024

During the scientific program at AAPOS 2024 in Boston, Dr. Idan Hecht presented the groundbreaking findings from a prospective randomized controlled trial evaluating the efficacy of RevitalVision in improving vision in Congenital Nystagmus patients. the study demonstrated statistically significant improvement in distance and near BCVA, and significant improvement in stereo and binocular functions, offering new hope for nystagmus patients, lacking alternative solutions to improve vision.

March 2024

RevitalVision Post Crosslinking Surgery Study Won the Best ASCRS Scientific Poster Award

RevitalVision’s study on post crosslinking surgery patients won the best scientific poster award at ASCRS 2024, and was selected for a live presentation.

This prospective, controlled randomized study evaluated the efficacy of RevitalVision’s vision-training software- program in improving best corrected vision in stable keratoconus patients post crosslinking surgery, and showed remarkable clinical outcomes!

The results demonstrated significant improvement in vision, with a mean improvement of 2.5 VA lines, as well as improvements in contrast sensitivity function (CSF) among crosslinked keratoconus patients who received RevitalVision treatment.

We thank Prof. Lional Raj, Prof. David Heber and the rest of Dr.Agarwal’s Eye Hospital Research team for their awarded work!

Feb 2024

AECOS (American-European Congress of Ophthalmic Surgery)

RevitalVision’s CEO, Yair Yahav, participated in the 2024 AECOS innovation forum, which featured eight top industry innovations. The forum was moderated by Mr. William Link, PhD.

April 2023

AAPOS 23 annual meeting- presenting poster with mid term study results

During the 48th annual meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS 23), Dr. Sigal Zmujack’s presented the mid-term results of two new controlled randomized studies evaluating RevitalVision’s efficacy in improving vision in nystagmus and amblyopia patients aged 9-55, which both showed significant anti-suppression effects.

January 2023

Narayana Nethralaya Eye Foundation – What & how does my child see Conference

RevitalVision CEO Yair Yahav was a guest speaker at the Narayana Nethralaya Eye Foundation symposium on Amblyopia, Binocular Vision, Cortical Visual Impairment, and Low Vision.

He presented a scientific & clinical review on Optimizing Cortical Visual Functions with RevitalVision.

Watch the full presentation

January 2023

A new published study on RevitalVision treatment

This independent study, which was published in Vision Development and Rehabilitation: COVD’s Digital Journal, evaluated the efficacy of RevitalVision’s perceptual-based vision training program, in improving visual acuity in adult amblyopic individuals beyond occlusion.

November22

Margalit Startup City Haifa- Digital Health Accelerator

We are proud to have been selected as one of the companies to participate in Margalit Startup City’s digital health accelerator in Haifa.

November22

Ophthalmology Innovation Source Summit (OIS)

Our CEO Yair Yahave presented at the OIS Israel (Ophthalmology Innovation Source Summit) during the MIXiii Health-Tech.IL conference between 9-10 November at the ICC in Jerusalem.

October 2022

Presenting at the ACADEMY 2022 SAN DIEGO

October 2022

RevitalVision at EPOS 2022 Munich

September 2022

Israel: A beacon of light helping with sight

This special feature article in GeekTime profiles innovative optics treatments and technologies from leading start-ups.

RevitalVision will present at ESCRS2022

We will be presenting at the 40th annual congress of The European Society for Cataract and Refractive Surgery (ESCRS) in Milan, Italy, from 16-19 September 2022.

May2022

RevitalVision at the AAO 2022 mid year press relase

March 2022

New randomized controlled trial on RevitalVision

Effects of Perceptual Learning on Deprivation Amblyopia in Children with Limbal Dermoid: A Randomized Controlled Trial

The study compared 2 groups of children with amblyopia after corneal transplant : One group received standard patching therapy and the second group received patching + RevitalVision.

The group that underwent RevitalVision therapy experienced statistically significant improvement in vision.

March 2022

RevitalVision will present at the AAPOS 2022 – Arizona

2022 Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), on March 23-27, 2022.

RevitalVision at HIMSS 22

This year, the Israel Export Institute together with the Foreign Trade Administration – Ministry of Economy & Industry will present 18Israeli Digital Health companies. And we are proud to be amongst these innovative companies

November 2021

RevitalVision on The Ophthalmologist

Yair Yahav, CEO and founder of RevitalVision, was interviewed in The Ophthalmologist about how we improve vision in adult amblyopia

July 2021

RevitalVision received reimbursement code in the USA

RevitalVision is a standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical Association (AMA).

3-6 November 2021

American Academy of Optometry Annual Meeting

We’re excited to be one of the exhibitors at the American Academy of Optometry Annual Meeting – which will be taking place in Boston. Visit us in the exhibit hall at booth #843

12-15 November 2021

American Academy of Ophthalmology Annual Meeting

Come meet our experts at the AAO annual meeting, taking place in New Orleans this November

21/02/2021

RevitalVision participates at MedinIsrael

02/11/2020

RevitalVision New Product Release

We are happy to announce the release of our new web vision training software application with RevitalVision new branding. This advance software, which is designed to improve vision by improving the brain visual processing, is easier to use and provides better patient feedback.

14/08/2020

RevitalVision recieves R&D grant from the Israeli Innovation Authority

01/08/2020

WSPOS – World Wide Webinar on Amblyopia – Sponsored by REVITALVISION

21-24 April 2021

REVITALVISION will participate at the upcoming 41st ESA (EUROPEAN STRABISMOLOGICAL ASSOCIATION)

Meeting in PARIS 21th /24th April 2021

2020

A New Adult Amblyopia study presented at AIOS 2020 (All India Ophthalmology Society)

meeting 2020 confirming again the efficacy of RevitalVision in improving vision in adult amblyopia

7 October

REVITALVISION will participate at the upcoming AAOPT (AMERICAN ACADEMY of OOPTOMETRY)

Meeting in Nashville, TN, USA 7-10 October

2020

Tel Aviv Medical Center is recruiting Age related Macular Degeneration patients for a REVITALVISION clinical study

A Proof-of-Concept, Prospective, Open label, Randomized Clinical Study Evaluating RevitalVision® Therapy for Improving Best Corrected Visual Acuity (BCVA) and Contrast Sensitivity Function (CSF) in Patients Suffering from stabler Age related Macular Degeneration (AMD)